Inflammatory bowel disease guidance published
New guidance on the care and treatment of patients with inflammatory bowel disease has been produced by the British Society of Gastroenterology (Gut 2011;60:571).
Recommendations on the use of immunosuppressive therapy have been revised and the guidance emphasises smoking cessation to improve outcomes in patients with Crohn’s disease. The guidance also supports once daily administration of mesalazine in maintenance of remission.
Anja St. Clair Jones, lead pharmacist for surgery and digestive diseases at Brighton and Sussex University Hospitals NHS Trust, stressed pharmacists’ roles in supporting patients to increase adherence to mesalazine, the importance of which is highlighted by the guidance.
Citation: The Pharmaceutical Journal URI: 11072919
Recommended from Pharmaceutical Press